Spravato® (esketamine) is a prescription nasal spray approved for adults with treatment-resistant depression (TRD) and for adults with major depressive disorder (MDD) experiencing acute suicidal thoughts or behaviors. Spravato is administered in a certified healthcare setting under the supervision of a qualified medical provider as part of a comprehensive treatment plan.

​

In clinical studies, many patients experienced a significant reduction in depressive symptoms, with some reporting improvement as early as 24 hours after treatment. Your provider will determine whether Spravato is an appropriate treatment option based on your individual symptoms, medical history, and treatment goals.